How to buy Becton Dickinson and Company (BDX) stocks

Becton Dickinson and Company is a medical instruments & supplies business based in the US. Becton Dickinson and Company shares (BDX) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $225.98 – a decrease of 1.55% over the previous week. Becton Dickinson and Company employs 70,000 staff and has a trailing 12-month revenue of around $20.6 billion.

Our top picks for where to buy Becton Dickinson and Company stock

Buy Becton Dickinson and Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Becton Dickinson and Company stock price (NYSE: BDX)

Use our graph to track the performance of BDX stocks over time.

Becton Dickinson and Company stocks at a glance

• Key figures

Information last updated 2025-03-13.

Latest market close	$225.98
52-week range	$215.84 - $250.85
50-day moving average more info button	$232.48
200-day moving average more info button	$232.83
Wall St. target price	$276.77
PE ratio more info button	37.57
Dividend yield more info button	$3.89 (1.78%)
Earnings per share (TTM) more info button	$5.93

Is it a good time to buy Becton Dickinson and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Becton Dickinson and Company price performance over time

Historical closes compared with the close of $225.98 from 2025-03-14

1 week (2025-03-07)	-1.55%
1 month (2025-02-14)	0.52%
3 months (2024-12-16)	-0.69%
6 months (2024-09-16)	-3.44%

1 year (2024-03-15)	-4.53%
2 years (2023-03-16)	-1.92%
3 years (2022-03-16)	242.7972
5 years (2020-03-16)	11.76%

Is Becton Dickinson and Company stock undervalued or overvalued?

Valuing Becton Dickinson and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Becton Dickinson and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Becton Dickinson and Company's P/E ratio

Becton Dickinson and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Becton Dickinson and Company shares trade at around 38x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Becton Dickinson and Company's PEG ratio

Becton Dickinson and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0234. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Becton Dickinson and Company's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Becton Dickinson and Company's EBITDA

Becton Dickinson and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.5 billion.

The EBITDA is a measure of a Becton Dickinson and Company's overall financial performance and is widely used to measure a its profitability.

Becton Dickinson and Company financials

Revenue TTM	$20.6 billion
Operating margin TTM	15.27%
Gross profit TTM	$9.6 billion
Return on assets TTM	3.7%
Return on equity TTM	6.84%
Profit margin	8.37%
Book value	$87.78
Market Capitalization more info button	$64 billion

TTM: trailing 12 months

Becton Dickinson and Company stock dividends

Dividend payout ratio: 28.61% of net profits

Recently Becton Dickinson and Company has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Becton Dickinson and Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Becton Dickinson and Company's case, that would currently equate to about $3.89 per share.

While Becton Dickinson and Company's payout ratio might seem fairly standard, it's worth remembering that Becton Dickinson and Company may be investing much of the rest of its net profits in future growth.

Becton Dickinson and Company's most recent dividend payout was on 30 March 2025. The latest dividend was paid out to all shareholders who bought their stocks by 9 March 2025 (the "ex-dividend date").

Have Becton Dickinson and Company's stocks ever split?

Becton Dickinson and Company's stocks were split on a 1025:1000 basis on 31 March 2022 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1025 shares. This wouldn't directly have changed the overall worth of your Becton Dickinson and Company stocks – just the quantity. However, indirectly, the new 2.4% lower stock price could have impacted the market appetite for Becton Dickinson and Company stocks, which in turn could have impacted Becton Dickinson and Company's stock price.

Becton Dickinson and Company stock price volatility

Over the last 12 months, Becton Dickinson and Company's stocks have ranged in value from as little as $215.8447 up to $250.8483. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Becton Dickinson and Company's is 0.379. This would suggest that Becton Dickinson and Company's stocks are less volatile than average (for this exchange).

Becton Dickinson and Company overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey..

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Becton Dickinson and Company is owned by insiders or institutions?
Currently 0.559% of Becton Dickinson and Company stocks are held by insiders and 93.639% by institutions. How many people work for Becton Dickinson and Company?
Latest data suggests 70,000 work at Becton Dickinson and Company. When does the fiscal year end for Becton Dickinson and Company?
Becton Dickinson and Company's fiscal year ends in September. Where is Becton Dickinson and Company based?
Becton Dickinson and Company's address is: 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 What is Becton Dickinson and Company's ISIN number?
Becton Dickinson and Company's international securities identification number is: US0758871091 What is Becton Dickinson and Company's CUSIP number?
Becton Dickinson and Company's Committee on Uniform Securities Identification Procedures number is: 075887109

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.